report banner

News in English

PostNews: Interim Report
Technician checking stem cell culture

Interim Report 1 2022/23

Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.
Learn more …
PostNews: Press Release
PHIs-CEO-Peter-Egelberg-at-the-RegeneratOR-Test-Bed-at-WFIRM_web

Wake Forest Institute for Regenerative Medicine Welcomes PHI

PHI visits the WFIRM to finalize an agreement concerning the automation of advanced quality control in large-scale biomanufacturing of regenerative therapies.
Learn more …
PostNews: Interim Report
blue-cells_black-bg_banner

Year-end Report 2021/22

Sales more than doubled in 2021/22, compared to previous financial year.
Learn more …
PostNews: Press Release
Artistic image of molecularly imprinted polymers (MIP).

Synthetic antibody patent awarded to PHI by Japan

PHI announces today that the Company has been granted a patent concerning synthetic antibodies in Japan.
Learn more …
PostNews: Press Release
Scientists in protective gear working in a cell laboratory.

PHI Enters Biomanufacturing Partnership with Wake Forest Institute for Regenerative Medicine

PHI and Wake Forest Institute for Regenerative Medicine recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs.
Learn more …
PostNews: Press Release
Close up of female hand signing an agreement

PHI Signs Subscription Commitments with Board Members, CEO and Owners

Subscription commitments corresponding to approximately 4 % of the initial rights issue (2.9 million SEK) have been signed with members of the company’s board, the company’s CEO and with owners.
Learn more …
191011121332